HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplementary figures and tables All Versions of this Article: 33/2/318    most recent 09031936.00000508v1 Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Zamanian, R. T. Articles by Doyle, R. L. Search for Related Content PubMed PubMed Citation Articles by Zamanian, R. T. Articles by Doyle, R. L.

Insulin resistance in pulmonary arterial hypertension

For affiliations, see Acknowledgements section.

CORRESPONDENCE: R. T. Zamanian, Division of Pulmonary and Critical Care Medicine, 300 Pasteur Dr., Room H3147, Stanford, CA 94305, USA. Fax: 1 6507255489. E-mail: zamanian{at}stanford.edu

Keywords: Insulin resistance, obesity, pulmonary arterial hypertension

Received: January 2, 2008
Accepted October 15, 2008

Although obesity, dyslipidemia and insulin resistance (IR) are well known risk factors for systemic cardiovascular disease, their impact on pulmonary arterial hypertension (PAH) is unknown. The present authors’ previous studies indicate that IR may be a risk factor for PAH. The current study has investigated the prevalence of IR in PAH and explored its relationship with disease severity.

Clinical data and fasting blood samples were evaluated in 81 nondiabetic PAH females. In total, 967 National Health and Nutrition Examination Surveys (NHANES) females served as controls. The fasting triglyceride to high-density lipoprotein cholesterol ratio was used as a surrogate of insulin sensitivity.

While body mass index was similar in NHANES versus PAH females (28.6 versus 28.7 kg·m^–2), PAH females were more likely to have IR (45.7 versus 21.5%) and less likely to be insulin sensitive (IS; 43.2 versus 57.8%). PAH females mostly (82.7%) had New York Heart Association (NYHA) class II and III symptoms. Aetiology, NYHA class, 6-min walk-distance and haemodynamics did not differ between IR and IS PAH groups. However, the presence of IR and a higher NYHA class was associated with poorer 6-months event-free survival (58 versus 79%).

Insulin resistance appears to be more common in pulmonary arterial hypertension females than in the general population, and may be a novel risk factor or disease modifier that might impact on survival.